블로그
- [U.S. FDA] FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with R Food and Drug Administration granted accelerated approval to Tzield (teplizumab) for a new indication , to delay the decline of insulin production in pediatric patients ages 8 through 17 years who have been
- [FDA, 200616] 키트루다, 고형암 환자 대상 허가 29%, CR 4%, PR 25%. mDoR not reached On June 16, 2020, the Food and Drug Administration granted accelerated progressed following prior treatment and who have no satisfactory alternative treatment options.